Resources
187 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 5/5/2024 (updated 5/7/2024)
The U.S. Department of Health & Human Services released details of a plan for more than 200 actions across the federal government to address high rates of suicide.
Posted 5/5/2024 (updated 5/7/2024)
The four-module implementation toolkit developed by the National Center on Substance Abuse and Child Welfare offers strategies to develop peer support specialist programs for parents affected by substance use—whose children and families are involved with child welfare.
Posted 5/5/2024 (updated 5/7/2024)
The MaineHealth Substance Use Training team has created a toolkit for extended-release injectable buprenorphine (Sublocade).
Posted 4/26/2024
The Nitazenes Overview resource created by RCORP-TA describes what nitazenes are, how to determine if they are in your community, and how to prevent and respond to overdoses due to nitazenes. Additional resources are also provided to learn more about nitazenes.
Posted 4/16/2024 (updated 4/24/2024)
Adverse childhood experiences (ACEs) are events of abuse, neglect, and household dysfunction that occur between birth and 17 years of age. Multiple studies established the association between ACEs, risky behaviors, and poor physical and mental health outcomes in childhood and beyond. Rural and minority children often have higher rates of ACEs exposure than their peers.
Posted 3/29/2024 (updated 4/4/2024)
Posted 3/29/2024 (updated 4/4/2024)
Posted 3/29/2024 (updated 4/4/2024)
During this session, participants planned to learn how to build trust and break down barriers with hard to reach populations.
Posted 2/29/2024 (updated 3/28/2024)
The 2024 RCORP-Behavioral Health Care Support Onboarding Packet includes resources, tools, and strategies to support grant-funded activities, along with information on accessing TA.
Posted 2/23/2024 (updated 3/28/2024)
his study assessed the degree in which health care professionals who were practicing within primary care or were likely to come in contact with patients with opioid use disorder (OUD) were endorsing misinformation about buprenorphine and if this affected their willingness to care for patients with OUD.